Urologic Oncology Research Training Grant

泌尿肿瘤学研究培训补助金

• 批准号: 8538759
• 负责人: PETER T SCARDINO
• 金额: $ 26.67万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8538759
• 关键词: Grant; Research Training; Urologic Oncology

DESCRIPTION (provided by applicant): The goal of the T32 research training program in urologic oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) is to train qualified clinician-scientists to be independent investigators in translational research and to progress to full-time academic positions. Dedicated research training in urologic oncology is essential to the mission of the National Cancer Institute (NCI) to eliminate suffering and death from cancer: genitourinary cancers comprise nearly one third of all non-skin cancers and cause 10% of all cancer deaths in the US. T32 fellows gain direct experience in biomedical research by working full-time for 2 years with established basic and translational research scientists. Fellows are also required to participate in structured, multidisciplinary conferences and to present their work at MSKCC seminars and national meetings. T32 preceptors represent the departments of Surgery, Epidemiology and Biostatistics, Medicine, Radiology, and Pathology, as well as 4 of the major research programs at the Sloan-Kettering Institute: Cell Biology, Immunology, Molecular Biology, and Molecular Pharmacology and Chemistry. Areas of research include cancer genetics; signals and pathways involved in the control of cell proliferation; protein targeting; tumor immunology, immunotherapy, and clinical therapeutics, among others. Although fellows may also undertake 1 year of clinical training, they have no clinical responsibilities during their research years unless it is integral to their research project. Most T32 fellows spend 2.5 to 3.5 years completing all research and clinical training. This T32 training grant will continue to support 4 postdoctoral fellows (typically 2 new and 2 continuing trainees) per year. All T32 candidates must have an MD, must have completed training in urology at a residency program approved by the Accreditation Council for Graduate Medical Education (ACGME), and must be board-eligible urologists. T32 fellows usually enter the program during PGY-6 or PGY-7. RELEVANCE: MSKCC's T32 program in urologic oncology trains qualified clinician-scientists for careers focused on eliminating suffering and death from urologic cancers, which comprise 31% of all non-skin cancers and cause 10% of all cancer deaths in the US. To date, 95% of the graduates have matriculated to faculty positions and are engaged in research aimed at understanding and overcoming these cancers.

描述（由申请人提供）：纪念斯隆-凯特琳癌症中心 (MSKCC) 泌尿肿瘤学 T32 研究培训计划的目标是培训合格的临床医生科学家成为转化研究的独立研究者，并晋升为全职学术职位。泌尿肿瘤学方面的专门研究培训对于美国国家癌症研究所 (NCI) 消除癌症带来的痛苦和死亡的使命至关重要：泌尿生殖系统癌症占所有非皮肤癌的近三分之一，并导致美国所有癌症死亡的 10%。 T32 研究员通过与知名基础和转化研究科学家全职工作 2 年，获得生物医学研究的直接经验。研究员还需要参加结构化的多学科会议，并在 MSKCC 研讨会和全国会议上展示他们的工作。 T32 导师代表外科、流行病学和生物统计学、医学、放射学和病理学系，以及斯隆-凯特琳研究所的 4 个主要研究项目：细胞生物学、免疫学、分子生物学以及分子药理学和化学。研究领域包括癌症遗传学；参与细胞增殖控制的信号和途径；蛋白质靶向；肿瘤免疫学、免疫治疗和临床治疗等。尽管研究员也可以接受一年的临床培训，但他们在研究期间不承担临床责任，除非这是他们研究项目的一部分。大多数 T32 研究员花费 2.5 至 3.5 年完成所有研究和临床培训。这笔 T32 培训补助金将继续每年支持 4 名博士后研究员（通常是 2 名新学员和 2 名继续培训生）。所有 T32 候选人必须拥有医学博士学位，必须在研究生医学教育认证委员会 (ACGME) 批准的住院医师计划中完成泌尿科培训，并且必须是符合委员会资格的泌尿科医生。 T32 研究员通常在 PGY-6 或 PGY-7 期间进入该项目。 相关性：MSKCC 的泌尿肿瘤学 T32 项目培训合格的临床医生科学家，致力于消除泌尿系统癌症带来的痛苦和死亡，泌尿系统癌症占所有非皮肤癌的 31%，占美国所有癌症死亡人数的 10%。迄今为止，95% 的毕业生已被录取担任教​​职，并从事旨在了解和克服这些癌症的研究。